How to buy Terns Pharmaceuticals stock

Terns Pharmaceuticals, Inc is a biotechnology business based in the US. Terns Pharmaceuticals shares (TERN) are listed on the NASDAQ and all prices are listed in US Dollars. Terns Pharmaceuticals employs 30 staff and has a market cap (total outstanding shares value) of 0.00.

Terns Pharmaceuticals share price

Use our graph to track the performance of TERN stocks over time.

Terns Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-04-21.

52-week range	$14.83 - $28.36
50-day moving average	$21.28
200-day moving average	$21.12
Wall St. target price	$29.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Terns Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Terns Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Terns Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Terns Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-39.83%
Return on equity TTM	-68.73%
Profit margin	0%
Book value	N/A
Market capitalisation	$455.3 million

TTM: trailing 12 months

Shorting Terns Pharmaceuticals shares

There are currently 1.5 million Terns Pharmaceuticals shares held short by investors – that's known as Terns Pharmaceuticals's "short interest". This figure is 70.7% up from 897,027 last month.

There are a few different ways that this level of interest in shorting Terns Pharmaceuticals shares can be evaluated.

Terns Pharmaceuticals's "short interest ratio" (SIR)

Terns Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Terns Pharmaceuticals shares currently shorted divided by the average quantity of Terns Pharmaceuticals shares traded daily (recently around 226784.44444444). Terns Pharmaceuticals's SIR currently stands at 6.75. In other words for every 100,000 Terns Pharmaceuticals shares traded daily on the market, roughly 6750 shares are currently held short.

To gain some more context, you can compare Terns Pharmaceuticals's short interest ratio against those of similar companies.

• Hepion Pharmaceuticals (HEPA.US): 0.61
• Intercept Pharmaceuticals (ICPT.US): 6.74
• Mirum Pharmaceuticals (MIRM.US): 4.76

However Terns Pharmaceuticals's short interest can also be evaluated against the total number of Terns Pharmaceuticals shares, or, against the total number of tradable Terns Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Terns Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Terns Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.1126% of the tradable shares (for every 100,000 tradable Terns Pharmaceuticals shares, roughly 113 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Terns Pharmaceuticals.

Find out more about how you can short Terns Pharmaceuticals stock.

Terns Pharmaceuticals share dividends

We're not expecting Terns Pharmaceuticals to pay a dividend over the next 12 months.

Have Terns Pharmaceuticals's shares ever split?

Terns Pharmaceuticals's shares were split on a 1000:50 basis on 3 November 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1000 shares. This wouldn't directly have changed the overall worth of your Terns Pharmaceuticals shares – just the quantity. However, indirectly, the new 95% lower share price could have impacted the market appetite for Terns Pharmaceuticals shares which in turn could have impacted Terns Pharmaceuticals's share price.

Terns Pharmaceuticals overview

Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Foster City, California. .

Frequently asked questions

• What percentage of Terns Pharmaceuticals is owned by insiders or institutions?

  Currently 1.137% of Terns Pharmaceuticals shares are held by insiders and 50.022% by institutions.

• How many people work for Terns Pharmaceuticals?

  Latest data suggests 30 work at Terns Pharmaceuticals.

• When does the fiscal year end for Terns Pharmaceuticals?

  Terns Pharmaceuticals's fiscal year ends in December.

• Where is Terns Pharmaceuticals based?

  Terns Pharmaceuticals's address is: 1065 East Hillsdale Boulevard, Foster City, CA, United States, 94404